These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35704263)

  • 1. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D; Banerjee D
    Curr Heart Fail Rep; 2022 Aug; 19(4):191-199. PubMed ID: 35704263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
    Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
    Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
    Rossignol P; Silva-Cardoso J; Kosiborod MN; Brandenburg V; Cleland JG; Hadimeri H; Hullin R; Makela S; Mörtl D; Paoletti E; Pollock C; Vogt L; Jadoul M; Butler J
    Pharmacol Res; 2022 Aug; 182():106277. PubMed ID: 35662631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden.
    Kim K; Fagerström J; Chen G; Lagunova Z; Furuland H; McEwan P
    BMC Nephrol; 2022 Aug; 23(1):281. PubMed ID: 35953778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
    Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
    Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel approaches to management of hyperkalaemia in kidney transplantation.
    Rizk J; Quan D; Gabardi S; Rizk Y; Kalantar-Zadeh K
    Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):27-37. PubMed ID: 33027094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives.
    Llubani R; Vukadinović D; Werner C; Marx N; Zewinger S; Böhm M
    Curr Heart Fail Rep; 2018 Dec; 15(6):390-397. PubMed ID: 30421355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study.
    Rastogi A; Pollack CV; Sánchez Lázaro IJ; Lesén E; Arnold M; Franzén S; Allum A; Hernández I; Murohara T; Kanda E
    Clin Kidney J; 2024 May; 17(5):sfae083. PubMed ID: 38699484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalemia in heart failure.
    Sidhu K; Sanjanwala R; Zieroth S
    Curr Opin Cardiol; 2020 Mar; 35(2):150-155. PubMed ID: 31833959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
    Gregg LP; Navaneethan SD
    Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.